Navigation Links
Multistage nanovector system provides sustained delivery of siRNA cancer therapeutic in mice
Date:5/5/2010

New research by scientists at The University of Texas Health Science Center at Houston (UTHealth) and The University of Texas M. D. Anderson Cancer Center could make it easier for patients to use a family of promising experimental cancer therapeutics known as small interfering RNA (siRNA).

siRNA is a part of an innovative strategy to disrupt the activity of cancer-related genes that has broad applications to other diseases.

In the May 1 issue of Cancer Research, the scientists reported that a multistage nanovector system for the delivery of siRNA significantly lengthened the therapeutic effects of the treatment in two independent mouse models of advanced ovarian cancer.

The researchers reported that a single intravenous dose of siRNA targeting the EphA2 oncoprotein provided the same tumor shrinkage for three weeks as that now achieved by six doses over the same period.

"The multistage delivery system is revolutionary in that it allows the therapeutic payloads to cross the biological barriers in the body and reach their target. It further helps release agents over long periods of time directly into the bloodstream, which is unprecedented," said Mauro Ferrari, Ph.D., chairman of the Department of NanoMedicine and Biomedical Engineering at The University of Texas Medical School at Houston, which is part of UTHealth. "We are very excited about the results of this paper, since it provides the first validation of the therapeutic advantages of the multistage delivery system in animal models of cancer."

The multistage nanovector system is composed of nanoporous silicon carrier particles that are about 100 times smaller than a strand of hair, which can be loaded with tiny bubbles of fat called nanoliposomes containing siRNA. The system provides for the release of the nanoliposomes and their contents.

"This is an exciting development because RNA interference has worked well in an animal model but has such a short half-life that it requires frequent delivery. A three-week dosing period is much closer to the sustained dosing needed to properly test this therapy in clinical trials," said Anil Sood, M.D., professor in M.D. Anderson's Departments of Gynecological Oncology and Cancer Biology.

The multistage nanovector system was developed in Ferrari's laboratory and the liposomal siRNA was developed at M. D. Anderson.

"We have provided the first in vivo therapeutic validation of a novel, multistage siRNA delivery system for sustained gene silencing with broad applicability to pathologies," wrote Takemi Tanaka, Ph.D., a co-first author and a research assistant professor of nanomedicine and biomedical engineering at the UT Medical School at Houston, and the other investigators in the paper.

Gabriel Lopez-Berestein, M.D., professor of experimental therapeutics at M. D. Anderson, Sood, co-director of M. D. Anderson's Center for RNA Interference and Non-Coding RNA, and Ferrari are the senior authors.

"EphA2 is an important target because it's overexpressed in 70 percent of ovarian cancers and is strongly associated with poor survival and a higher likelihood of advanced or metastatic disease," said Lopez-Berestein. "It's also overexpressed in melanoma, breast and lung cancers with the same poor prospects for patients."

The protein is not present in normal tissue and cannot be attacked using more traditional drug approaches.


'/>"/>

Contact: Robert Cahill
Robert.Cahill@uth.tmc.edu
713-500-3030
University of Texas Health Science Center at Houston
Source:Eurekalert  

Related biology news :

1. Bursts of waves drive immune system soldiers toward invaders
2. Bioengineers at University of Pennsylvania devise nanoscale system to measure cellular forces
3. Obesity and the central nervous system -- the state of the art
4. How the plant immune system can drive the formation of new species
5. Upgraded IMG 2.3 Data Management System released by DOE JGI to eager user community
6. Systems Biology poised to revolutionize the understanding of cell function and disease
7. Europe needs collective effort on System Biology, says ESF Task Force
8. Cogent Systems and Northrop Grumman Reach Agreement to Settle Automated Fingerprint Identification Technology Suit and Create Strategic Alliance
9. Radiant Systems Selects BIO-key(R) Biometric Software for POS Solution
10. Fujitsu and HT Systems Partner to Provide Biometric Patient Identity Management
11. Fujitsu and HT Systems Partner to Provide Biometric Patient Identity Management
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Multistage nanovector system provides sustained delivery of siRNA cancer therapeutic in mice
(Date:3/24/2017)... MILAN , March 24, 2017 The Controller ... Deputy Controller Mr. Abdulla Algeen have received the prestigious international ... Continue Reading ... ... small picture) and Deputy Controller Abdulla Algeen (small picture on the right) ...
(Date:3/22/2017)... , March 21, 2017   Neurotechnology ... object recognition technologies, today announced the release of ... (SDK), which provides improved facial recognition using up ... on a single computer. The new version uses ... improve accuracy, and it utilizes a Graphing Processing ...
(Date:3/20/2017)... , March 20, 2017 PMD Healthcare announces ... spirometer and Wellness Management System (WMS), a remote, real-time ... in 2010, PMD Healthcare is a Medical Device, Digital ... mission dedicated to creating innovative solutions that empower people ... that intent focus, PMD developed the first ever personal ...
Breaking Biology News(10 mins):
(Date:4/20/2017)... Diego, CA (PRWEB) , ... April 20, 2017 , ... ... management of clinical trials worldwide, announced today that they were named one of the ... , which covers the latest developments in the pharmaceutical industry. , “We take pride ...
(Date:4/20/2017)... N.J. and PETACH TIKVAH, Israel ... BCLI), a leading developer of adult stem cell technologies for ... Executive Officer, will present at the Alliance for Regenerative Medicine,s ... Day on Thursday, April 27, 2017 at 09:40 EDT in ... Ralph Kern , MD, MHSc, Chief Medical Officer & ...
(Date:4/19/2017)... ... April 18, 2017 , ... A number of new instruments ... which is part of the Protein and Cell Analysis Education Webinar Series , ... this technology fits in current and future applications. , Many flow cytometers have ...
(Date:4/19/2017)... ... , ... Nobilis Therapeutics Announces Completion of Landmark NBTX-001 Clinical Trial ... its Upcoming Post Traumatic Stress Disorder Trial , Nobilis Therapeutics, Inc. announced ... of its NBTX-001, a xenon-based therapeutic in the treatment of Panic Disorder. ...
Breaking Biology Technology: